Overview

OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

This pilot study will provide preliminary data regarding the role of PIS in predicting the benefit of immune checkpoint inhibition with or without chemotherapy for high risk patients with TNBC and residual disease after effective neoadjuvant chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Georgetown University

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Capecitabine
Nivolumab